1. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations

   • Gabriel Pardo
   • David E. Jones

   Review Open access 06 September 2017 Pages: 2351 - 2374

2. Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations

   • Gabriel Pardo
   • David E. Jones

   Correction 23 October 2017 Pages: 2375 - 2377

3. Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis

   • Le Zhang
   • Josemir W. Sander
   • Dong Zhou

   Original Communication 09 October 2017 Pages: 2378 - 2386

4. A novel mutation of VAPB in one Chinese familial amyotrophic lateral sclerosis pedigree and its clinical characteristics

   • Yi-min Sun
   • Yi Dong
   • Jian-jun Wu

   Original Communication 09 October 2017 Pages: 2387 - 2393

   

5. Treatment outcome in patients with clinically defined carpal tunnel syndrome but normal electrodiagnostic test results: a randomized controlled trial

   • Floriaan G. C. M. De Kleermaeker
   • Jan Meulstee
   • Wim I. M. Verhagen

   Original Communication 09 October 2017 Pages: 2394 - 2400

   

6. The natural history of depressive symptoms in patients with incident Parkinson’s disease: a prospective cohort study

   • Jan Petter Larsen
   • Ingvild Dalen
   • Ole-Bjørn Tysnes

   Original Communication 14 October 2017 Pages: 2401 - 2408

   

7. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time

   • John Peters
   • Eric Williamson

   Original Communication 16 October 2017 Pages: 2409 - 2412

   

8. Prevalence and clinical characteristics of cortical superficial siderosis in patients with acute stroke

   • Satoshi Suda
   • Takashi Shimoyama
   • Kazumi Kimura

   Original Communication 23 October 2017 Pages: 2413 - 2419

   

9. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study

   • Sara Mariotto
   • Sergio Ferrari
   • Alberto Gajofatto

   Original Communication Open access 23 October 2017 Pages: 2420 - 2430

   

10. Characterization of Charcot–Marie–Tooth optic neuropathy

    • Benjamin Botsford
    • Laurel N. Vuong
    • Carlos E. Mendoza-Santiesteban

    Original Communication 23 October 2017 Pages: 2431 - 2435

    

11. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

    • Giancarlo Comi
    • Francesco Patti
    • For the Golden Study Group

    Original Communication Open access 23 October 2017 Pages: 2436 - 2449

    

12. Clinical implications of CT hyperdense artery sign in patients with acute middle cerebral artery occlusion in the era of modern mechanical thrombectomy

    • Seul Kee Kim
    • Byung Hyun Baek
    • Woong Yoon

    Original Communication 26 October 2017 Pages: 2450 - 2456

    

13. An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease

    • Benjamin R. Underwood
    • Zeyn W. Green-Thompson
    • Roger A. Barker

    Original Communication Open access 26 October 2017 Pages: 2457 - 2463

    

14. Characterisation of pain in people with hereditary neuropathy with liability to pressure palsy

    • Darren Beales
    • Robyn Fary
    • Tim Mitchell

    Original Communication 27 October 2017 Pages: 2464 - 2471

    

15. Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2

    • Federica Montagnese
    • Stefania Mondello
    • Benedikt Schoser

    Original Communication 30 October 2017 Pages: 2472 - 2480

    

16. Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy

    • Ivo Bozovic
    • Aleksandra Kacar
    • Ivana Basta

    Original Communication 30 October 2017 Pages: 2481 - 2486

    

17. Reversible amygdala enlargement: a longitudinal observation of a patient with elderly onset temporal lobe epilepsy

    • Takashi Matsudaira
    • Yoshio Omote
    • Yushi Inoue

    Letter to the Editors 24 October 2017 Pages: 2487 - 2490

    

18. Disease reactivation after switching from natalizumab to daclizumab

    • Timo Uphaus
    • Christoph Oberwittler
    • Stefan Bittner

    Short Commentary 03 October 2017 Pages: 2491 - 2494

    

19. Can developmental venous anomalies cause seizures?

    • Claire Dussaule
    • Pascal Masnou
    • Christian Denier

    Neurological Update 17 March 2017 Pages: 2495 - 2505

    

20. Cannabidiol as a treatment for epilepsy

    • William O. Pickrell
    • Neil P. Robertson

    Journal club Open access 09 November 2017 Pages: 2506 - 2508

21. Maksymilian Rose (1883–1937)

    • Katarzyna Pekacka-Falkowska
    • Michal K. Owecki
    • Anna Maria Pekacka

    Pioneers in Neurology Open access 18 August 2017 Pages: 2509 - 2510